CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
61.88
+1.51 (2.50%)
At close: Mar 6, 2026, 4:00 PM EST
61.88
0.00 (0.00%)
After-hours: Mar 6, 2026, 5:01 PM EST
CG Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 4.04 | 1.14 | 0.2 | 0.19 | 10.36 |
| Revenue Growth (YoY) | 254.70% | 458.33% | 6.81% | -98.16% | - |
| Cost of Revenue | 121.29 | 82.1 | 45.75 | 29.03 | 18.32 |
| Gross Profit | -117.25 | -80.96 | -45.55 | -28.84 | -7.96 |
| Selling, General & Admin | 73.53 | 33.7 | 9.9 | 6.41 | 4.65 |
| Operating Expenses | 73.53 | 33.7 | 9.9 | 6.41 | 4.65 |
| Operating Income | -190.77 | -114.67 | -55.45 | -35.25 | -12.61 |
| Interest Expense | - | - | - | -0 | -0.45 |
| Interest & Investment Income | 29.93 | 26.62 | 6.9 | 1.6 | - |
| Other Non Operating Income (Expenses) | -0.15 | 0 | -0.06 | -1.8 | -0.18 |
| EBT Excluding Unusual Items | -161 | -88.04 | -48.61 | -35.44 | -13.24 |
| Other Unusual Items | - | - | - | - | 0.4 |
| Pretax Income | -161 | -88.04 | -48.61 | -35.44 | -12.84 |
| Net Income | -161 | -88.04 | -48.61 | -35.44 | -12.84 |
| Preferred Dividends & Other Adjustments | - | - | 19.19 | 8.35 | 5.54 |
| Net Income to Common | -161 | -88.04 | -67.8 | -43.79 | -18.38 |
| Shares Outstanding (Basic) | 77 | 62 | 4 | 4 | 4 |
| Shares Outstanding (Diluted) | 77 | 62 | 4 | 4 | 4 |
| Shares Change (YoY) | 23.69% | 1343.03% | 15.77% | 2.48% | - |
| EPS (Basic) | -2.08 | -1.41 | -15.65 | -11.71 | -5.04 |
| EPS (Diluted) | -2.08 | -1.41 | -15.65 | -11.71 | -5.04 |
| Free Cash Flow | -132.48 | -78.95 | -45.68 | -29.82 | -13.75 |
| Free Cash Flow Per Share | -1.71 | -1.26 | -10.55 | -7.97 | -3.77 |
| Gross Margin | - | - | - | - | -76.86% |
| Operating Margin | -4722.13% | -10067.25% | -27180.88% | -18453.40% | -121.70% |
| Profit Margin | -3985.03% | -7729.50% | -33234.31% | -22925.65% | -177.48% |
| Free Cash Flow Margin | -3279.21% | -6931.26% | -22391.67% | -15611.52% | -132.76% |
| EBITDA | -189.33 | -114.63 | -55.43 | -35.23 | -12.6 |
| EBITDA Margin | - | - | - | - | -121.61% |
| D&A For EBITDA | 1.45 | 0.03 | 0.02 | 0.02 | 0.01 |
| EBIT | -190.77 | -114.67 | -55.45 | -35.25 | -12.61 |
| EBIT Margin | - | - | - | - | -121.70% |
| Revenue as Reported | 4.04 | 1.14 | 0.2 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.